Przejdź do zawartości
Merck

1356836

USP

Lamivudine

United States Pharmacopeia (USP) Reference Standard

Synonim(y):

2′,3′-Dideoxy-3′-thiacytidine, 3TC, Epivir, Epivir-HBV, Heptovir, Zeffix

Slide 1 of 1
Zaloguj się, aby wyświetlić ceny organizacyjne i kontraktowe.

Wybierz wielkość

200 MG

1910,00 zł

1910,00 zł

Skontaktuj się z Obsługą Klienta, aby uzyskać informacje na temat dostępności
Zamów zamówienie zbiorcze

Informacje o tej pozycji

Wzór empiryczny (zapis Hilla):
C8H11N3O3S
Numer CAS:
134678-17-4
Masa cząsteczkowa:
229.26
NACRES:
NA.24
PubChem Substance ID:
329750230
UNSPSC Code:
41116107
MDL number:
MFCD00869739

Kluczowe dokumenty

Wyświetl całą dokumentację

Przejdź do

Pomoc techniczna
Potrzebujesz pomocy? Nasz zespół doświadczonych naukowców chętnie Ci pomoże.
Pozwól nam pomóc

InChI

1S/C8H11N3O3S/c9-5-1-2-11(8(13)10-5)6-4-15-7(3-12)14-6/h1-2,6-7,12H,3-4H2,(H2,9,10,13)/t6-,7+/m0/s1

SMILES string

NC1=NC(=O)N(C=C1)[C@@H]2CS[C@H](CO)O2

InChI key

JTEGQNOMFQHVDC-NKWVEPMBSA-N

grade

pharmaceutical primary standard

API family

lamivudine

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

format

neat

Szukasz podobnych produktów? Odwiedź Przewodnik dotyczący porównywania produktów

Powiązane kategorie

Porównaj podobne pozycje

Wyświetl pełne porównanie

Pokaż różnice

1 of 4

Ta pozycja
BP802PHR1365Y0000518
Lamivudine United States Pharmacopeia (USP) Reference Standard

USP

1356836

Lamivudine

Lamivudine British Pharmacopoeia (BP) Reference Standard

BP802

Lamivudine

Lamivudine Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1365

Lamivudine

Lamivudine for system suitability 1 European Pharmacopoeia (EP) Reference Standard

Y0000518

Lamivudine for system suitability 1

manufacturer/tradename

USP

manufacturer/tradename

BP

manufacturer/tradename

-

manufacturer/tradename

EDQM

grade

pharmaceutical primary standard

grade

pharmaceutical primary standard

grade

certified reference material, pharmaceutical secondary standard

grade

pharmaceutical primary standard

format

neat

format

neat

format

neat

format

neat

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical
pharmaceutical small molecule

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical (small molecule)

API family

lamivudine

API family

lamivudine

API family

lamivudine

API family

lamivudine

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Lamivudine USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Abacavir and Lamivudine Tablets
  • Abacavir, Lamivudine and Zidovudine Tablets
  • Lamivudine
  • Lamivudine and Zidovudine Tablets
  • Lamivudine Oral Solution
  • Lamivudine Tablets

Biochem/physiol Actions

Lamivudine is a potent nucleoside analog reverse transcriptase inhibitor (nRTI).
Lamivudine is a potent nucleoside analog reverse transcriptase inhibitor (nRTI). It is an analogue of cytidine, and can inhibit both types (1 and 2) of HIV reverse transcriptase as well as the reverse transcriptase of hepatitis B. It needs to be phosphorylated to its triphosphate form before it is active. 3TC-triphosphate also inhibits cellular DNA polymerase.

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Other Notes

Sales restrictions may apply.
Ta strona może zawierać tekst przetłumaczony maszynowo.

comparable product

Numer produktu
Opis
Cennik

related product

Numer produktu
Opis
Cennik

pictograms

Health hazard
GHS08

signalword

Warning

Klasa składowania

11 - Combustible Solids

flash_point_f

Not applicable

flash_point_c

Not applicable

target_organs

Blood

Hazard Classifications

Aquatic Chronic 3 - Repr. 2 - STOT RE 2

Wybierz jedną z najnowszych wersji:

Certyfikaty analizy (CoA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Dokumenty section.

Proszę o kontakt, jeśli potrzebna jest pomoc Obsługa Klienta

Masz już ten produkt?

Dokumenty związane z niedawno zakupionymi produktami zostały zamieszczone w Bibliotece dokumentów.

Odwiedź Bibliotekę dokumentów

Youwen Tan et al.
PloS one, 7(3), e32789-e32789 (2012-04-06)
Several recent reports have demonstrated that tyrosine (Y)-methionine (M)-aspartic acid (D)-aspartic acid (D) (YMDD) motif mutations can naturally occur in chronic HBV patients without antiviral treatment such as lamivudine therapy. This paper aims to assess the overall spontaneous incidence and
Zhongjie Shi et al.
Obstetrics and gynecology, 116(1), 147-159 (2010-06-23)
To evaluate efficacy of lamivudine in reducing in utero transmission of hepatitis B virus (HBV). A database was constructed from Medline, EMBASE, Cochrane Library, National Science Digital Library, China Biological Medicine Database, and through contact with experts in the field
Stephen Weller et al.
Journal of acquired immune deficiency syndromes (1999), 66(4), 393-398 (2014-05-07)
The integrase inhibitor dolutegravir and nucleoside analogues abacavir and lamivudine are once-daily treatment options for HIV. This study (NCT01622790) evaluated, first, the bioequivalence (BE) of a fixed-dose combination (FDC) tablet containing dolutegravir 50 mg, abacavir 600 mg, and lamivudine 300
Kuo-Chih Tseng et al.
Antiviral therapy, 19(8), 755-764 (2014-03-04)
It is still inconclusive whether chronic hepatitis B (CHB) patients with persistently normal alanine aminotransferase (PNALT) should receive nucleoside/nucleotide analogues. This study is to evaluate the efficacy of entecavir in improving liver histology in CHB patients with PNALT. In this
Suzaan Marais et al.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 59(11), 1638-1647 (2014-08-12)
The immunopathogenesis of tuberculosis-associated immune reconstitution inflammatory syndrome (IRIS) remains incompletely understood, and we know of only 1 disease site-specific study of the underlying immunology; we recently showed that Mycobacterium tuberculosis culture positivity and increased neutrophils in the cerebrospinal fluid
Wyświetl wszystkie powiązane dokumenty

Questions

Reviews

No rating value

Active Filters

Nasz zespół naukowców ma doświadczenie we wszystkich obszarach badań, w tym w naukach przyrodniczych, materiałoznawstwie, syntezie chemicznej, chromatografii, analityce i wielu innych dziedzinach.

Skontaktuj się z zespołem ds. pomocy technicznej